NeuroMetrix Reports DPNCheck to be Featured at Upcoming 33rd Japan Society of Diabetic Complications Annual Meeting in Tokyo ...
October 18 2018 - 11:00AM
NeuroMetrix, Inc. (Nasdaq:NURO), reported that DPNCheck®, its
rapid, point-of-care test for diabetic peripheral neuropathy (DPN),
will be featured in several scientific sessions at the 33rd Japan
Society of Diabetic Complications Meeting in Tokyo on October 19
and 20, 2018.
Relevant scientific sessions include:
- “Benefit of Japanese Reference Values for Sural Nerve Using
DPNCheck” • Wakayama Medical University
study group, led by Hideyuki Sasaki M.D., Ph.D. (Professor,
Division of Diabetes and Metabolism)
- “Diagnostic Probability of DPN Using Simple Criteria”
• Aichi Medical University group, led by
Professor Jiro Nakamura M.D., Ph.D. (Professor, Diabetes
Division)
Immediately following the meeting, Fukuda Denshi Co. Ltd.,
exclusive distributor for DPNCheck in Japan, will host a roundtable
discussion focused on the clinical importance of early diagnosis of
diabetic peripheral neuropathy, quantitative measurement,
guidelines for staging of diabetic peripheral neuropathy for
practical intervention, as well as appropriate tools for use in a
clinical setting. Roundtable participants will include leading
Japanese academic clinicians and researchers. Shai N. Gozani, M.D.,
Ph.D., NeuroMetrix President and CEO, will participate in the
roundtable.
About DPNCheck
DPNCheck is a fast, accurate, and quantitative nerve conduction
test that is used to evaluate diabetic peripheral neuropathy (DPN).
It is designed to be used by clinicians at the point-of-care to
objectively detect, stage, and monitor DPN. DPNCheck has been
available since 2011 and over a million diagnostic tests worldwide
have been performed using the technology. See DPNCheck.com for more
information.
About Fukuda Denshi
Fukuda Denshi is a world leader in cardiology instrumentation,
patient monitoring and ultrasound technologies. Fukuda Denshi
creates medical technology with the purpose of providing relevant
information easily, clearly, quickly, and reliably. Fukuda Denshi
believes that technology must be transparent and dependable or it
can confuse rather than clarify the patient's situation. For
more information, please visit Fukuda Denshi.com.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining
neurostimulation and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes.
The company's lead therapeutic product is Quell®, an
over-the-counter wearable therapeutic device for chronic pain. The
company also markets DPNCheck, a rapid point-of-care test for
diabetic neuropathy, which is the most common long-term
complication of Type 2 diabetes. For more information, please visit
NeuroMetrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief
Financial Officer Neurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Sep 2023 to Sep 2024